Bristol gets priority review for grant-host disease preventive

 U.S. Food and Drug Administration assigned an action date of December 23, 2021

The sBLA is supported by the Phase 2 ABA2 Trial evaluating Orencia in adults and children to prevent aGvHD

If approved, Orencia would become the first therapy for the prevention of aGvHD

https://finance.yahoo.com/news/u-food-drug-administration-accepts-105900235.html